New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AbbVie Inc.

ABBV

Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

288.56 5.05 +1.78%
Market cap
$501.2B
P/E
48.8×
Fwd P/E FY26e
37.6×
Dividend yield
2.44%
F-score
8/9
ROIC
20.2%
Net debt / EBITDA
2.6×
Payout ratio
1.2×

AbbVie Inc. 10-Q filed Aug 4, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 3:17 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 9, 2025: 14 added · 1 removed · 28 modified; 10 with only figures updated; 6 moved without change

  1. Modified

    The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of March 31June 30, 2025 and December 31, 2024 and the results of operations for the three and six months ended March 31June 30, 2025 and 2024. This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.”